Kazia Therapeutics Limited

NasdaqCM KZIA

Kazia Therapeutics Limited Free Cash Flow for the year ending June 30, 2024: USD -6.39 M

Kazia Therapeutics Limited Free Cash Flow is USD -6.39 M for the year ending June 30, 2024, a 36.67% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Kazia Therapeutics Limited Free Cash Flow for the year ending June 30, 2023 was USD -10.09 M, a 35.79% change year over year.
Kazia Therapeutics Limited Free Cash Flow for the year ending June 30, 2022 was USD -15.71 M, a -129.95% change year over year.
Kazia Therapeutics Limited Free Cash Flow for the year ending June 30, 2021 was USD -6.83 M, a -12.32% change year over year.
Kazia Therapeutics Limited Free Cash Flow for the year ending June 30, 2020 was USD -6.08 M, a -29.00% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: KZIA

Kazia Therapeutics Limited

CEO	Dr. John Edwin Friend II, M.D.
IPO Date	Jan. 6, 1999
Location	Australia
Headquarters	Three International Towers
Employees	9
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key trends

Past 5 years